PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for ...

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of

Related Keywords

United States ,Boston ,Massachusetts ,Laurence Watts ,Sarah Sutton ,James Mcarthur ,Nasdaq ,Pepgen Inc ,Gilmartin Group ,Drug Administration ,Orphan Drug Act ,Rare Pediatric Disease ,Orphan Drug ,Enhanced Delivery Oligonucleotide ,Duchenne Muscular Dystrophy ,Private Securities Litigation Reform Act ,